Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

Known as: Metastatic Non-Squamous Non-Small Cell Lung Cancer 
A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.
National Institutes of Health

Related topics

Related topics

14 relations
ChestEGFR Gene MutationEGFR geneEpithelial Cells
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer.
8095 Background: Bavituximab (B) is a monoclonal antibody against phosphatidylserine (PS) with a selective tumor vascular… Expand
Is this relevant?
2017
2017
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
BackgroundDelta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the maintenance of chemotherapy-resistant cancer stem… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2015
2015
Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer
Toxic epidermal necrolysis (TEN) is a rare acute life-threatening mucocutaneous disorder that is mostly drug-related (80%–95… Expand
Is this relevant?
2015
2015
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first…
OBJECTIVES To compare the activity and tolerance of the consecutive administration of four active chemotherapeutic agents in… Expand
Is this relevant?
2014
2014
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
Background:This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non… Expand
  • table 2
  • table 1
  • figure 1
  • table 3
Is this relevant?
2014
2014
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
INTRODUCTION Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small… Expand
Is this relevant?
2014
2014
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung…
BACKGROUND In the Iressa Pan-ASia Study (IPASS), gefitinib claimed improved progression-free survival (PFS) versus carboplatin… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
Pemetrexed-induced anaphylaxis
Pemetrexed is a folate antimetabolite approved for the treatment of mesothelioma and locally advanced or metastatic non-squamous… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non…
EGFR tyrosine kinase inhibitors (EGFR-TKIs) are recommended as first-line therapy in patients with advanced, recurrent, or… Expand
Is this relevant?
2009
2009
Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC).
e19023 Background: Bevacizumab (B), in addition to platinum-based chemotherapy, is indicated for 1st-line treatment of p with… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE